Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Pacira Pharma (PCRX) Misses Q1 EPS by 15c
May 4, 2017 8:02 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of ($0.19), $0.15 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $69.3 million versus the consensus estimate of $70.24 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More